Sponsored by
Bryan Hendin
Founder and President, Apollo Applied Research
Since an Ontario court ruled it was unconstitutional to block access to cannabis for medical patients, the use of medical cannabis has grown dramatically in this country.
Since 2001, Canadian doctors have been prescribing it to treat many conditions, ranging from seizure disorders and nausea caused by chemotherapy to anxiety, depression, PTSD, and insomnia. It has proven particularly effective as a treatment for arthritis and chronic pain. It’s clear that medical cannabis is a viable treatment option that has a bright future in health care.
Although medical cannabis is becoming more prevalent, and a growing number of Canadians are interested in it, the solution is more than a prescription.
Receiving the right prescription and treatment plan is essential
There are many strains of cannabis and dozens of cannabis compounds including CBD and THC. A particular strain could affect three patients in three different ways depending on genetics, other medications being taken, and other health factors.
One size does not fit all, and this makes it difficult for patients to find the best treatment plans for their respective conditions without guidance. With the legalization of recreational cannabis looming, the amount of information being released is expanding by the day, which makes the challenge even greater. To benefit fully from medical cannabis, patients should consult with specially trained physicians who can help them develop personalized treatment plans to ensure they get the most relief and effective results possible.
Medical cannabis is a viable treatment option that has a bright future in health care.
This is the mission for Apollo CannabisClinics, a network of cannabis-trained physicians across Canada who take an evidence-based approach to treatment with medical cannabis. Many of their patients are suffering from chronic pain and looking for an alternative to opioids.
Apollo Founder and President Bryan Hendin says his clinics, which provide ongoing education, support, and monitoring for patients, have helped to improve the quality of life for many patients.
“We can show through validated research that 80 percent of patients have been able to reduce or discontinue opioid use after a month of treatment with medical cannabis,” he says. The clinical observational study was conducted by Apollo’s research division and is now in peer review.
Hendin emphasizes that Apollo patients have been able to take control of their health by working with physicians and cannabis experts to develop with personalized treatment plans. Each plan is based on the patient’s specific needs and comfort with medical cannabis, which is critical to success.
Research will continue to prove that medical cannabis is effective. But Hendin says that, to get the best possible result, physician and patient must go through a process together. He encourages patients seeking relief from pain and other conditions to seek information available from clinics like Apollo to learn how a medical cannabis treatment plan may help.